BRING-UP Prevention
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHeart Care Foundation
About this trial
The aim of this observational study is to assess in patients with a documented athero-thrombotic event: coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral artery disease (PAD):
* the level of adherence to guideline recommendations with the assumption to improve the rate of patients at goal for cholesterol levels. * the level of adherence to guideline recommendations and the rate of patients at goal for the other relevant and modifiable risk factors for cardiovascular event recurrence.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Both sexes at birth, age ≥18 years
Prior Acute Coronary Syndrom (ACS)
Prior Coronary Artery Bypass Graft (CABG)
Prior Percutaneous Coronary Intervention (PCI)
Disqualifiers
Active neoplasia or very severe disease compromising short-medium term life expectancy.
Participation in interventional studies.
Patients already enrolled into the study from another participating center or in the previous enrolling phase.
Trial population
Patients discharged (after ordinary hospitalisation or day hospital) or managed as outpatients with a documented prior athero-thrombotic event: coronary artery disease (CAD), cerebrovascular disease (CVD), peripheral artery disease (PAD).
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Adherence to guideline for cholesterol level
Rate of patients at goal for LDL cholesterol (\<55 mg/dL)
Time frame
6 monthsSecondary outcomes
1
Adherence to guideline for other risk factors
Rate of patients at goal for BP (SBP/DBP \< 130/80 mmHg) and at goal for HbA1c (\<7%) as well as rate of overweight patients (BMI \> 27 kg/m2) who show a weight loss of at least 10%
Time frame
6 monthsOther outcomes
1
Patients' outcome
Rate of occurrence of clinical events (all-cause deaths, recurrent athero-thrombotic events, all cause hospitalizations, specific causes of death and hospitalizations) during the 12 follow-up of each enrolment phase.
Time frame
12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov